 CAMBRIDGE, Mass., Sept. 02, 2021 GLOBE NEWSWIRE -- TCR2 Therapeutics Inc. Nasdaq: TCRR, a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the U.S. Food and Drug Administration FDA has granted the Company Orphan Drug Designation ODD to gavo-cel for the treatment of cholangiocarcinoma. New clinical data from the dose escalation portion of the Phase 12 clinical trial of gavo-cel in patients with treatment refractory mesothelin-expressing solid tumors will be highlighted as part of an oral presentation at the European Society for Medical Oncology on September 17 at 14:20 CEST 8:20AM EST and will include data for gavo-cel in malignant mesothelioma, ovarian cancer and cholangiocarcinoma. 